After 6 months of vaccination, Pfizer’s effectiveness stands at 86%
After six months of using Pfizer in the US and around the world, the company’s CEO says that effectiveness stays at 84%. Albert Bourla says that massive vaccination started six months ago. The success rate of the vaccine was above 90% at the start of 2021. At the end of the six months vaccination campaigns, Bourla announced that according to data, the vaccine’s effectiveness dropped to 84%.
Table of Contents
Data from Israel
The CEO of Pfizer says that data from Israel was interesting. Albert noted that Israel was one of the first countries to start massive vaccination with Pfizer. The data shows that the vaccine helped 100% of the double-shot person from hospitalization in the first three months of the campaigns. In the last three months, that rate dropped to 90%. Bourla believes that effectiveness is very strong and helps everyone against hospitalization or, even worse – against death.
Immune booster against Delta variant
During the interview, Albert Bourla said that the immune booster is ready. It will help against the Delta variant. As you may know, the Delta variant (origin from India) is dangerous. There is no particular vaccine against the Delta variant. It’s dangerous and spreads very fast, in a matter of seconds. 50%+ of deaths in the last two months in the world comes from Delta. Pfizer’s CEO noted that the immune booster would be the third dose of the vaccine. It will be a protector against Delta. On the other hand, Anthony Fauci predicts more dangerous variants in the upcoming months.
Watch full interview with CEO of the company on why Pfizer is effective and why you need immune booster against Delta variant
$7.8 billion of covid shots in seconds quarter of 2021
The CEO of the company also talked about the financial success in the second quarter of 2021. Bourla noted that Pfizer made $7.8 in the 2nd quarter only from selling vaccine shots. The company raised the forecast of ‘yearly shots’ to $33+ billion. At first, Pfizer’s sales forecast was $26 billion in 2021. As the Delta variant spreads fast, the company is ready to sell more vaccine shots in the next two quarters of the year.
Watch CNBC Business' report on Pfizer's financial expectations and how they make more than competitors